Gastroparesis. Malabsorption due to intolerance, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group: Metoclopramide infusion with rate of 40mg/24-hour for 7 days. Intervention 2: Control group: Metoclopramide intravenous injection with dose of 10 mg every 6 hours
Treatment - Drugs
Intervention group: Metoclopramide infusion with rate of 40mg/24-hour for 7 days
Control group: Metoclopramide intravenous injection with dose of 10 mg every 6 hours for 7 days.
Sponsors
Vice Chancellor for Research, Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Critically ill adult patients who are candidate to receive metoclopramide as prokinetic agent due to enteral feeding intolerance (defined as gastric residual volume equal to or greater than 250 ml concomitant with symptoms of nausea, vomiting, and regurgitation or gastric residual volume more than 500 ml during 24 hours of enteral feeding) will be included. Exclusion criteria: Patients with metoclopramide allergy; metoclopramide intolerance; uncontrolled ventricular arrhythmia; extrapyramidal reactions; seizure; head trauma; signs and symptoms of increased intracranial pressure
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Enteral feeding intolerance. Timepoint: Daily. Method of measurement: Gastric residual will be measured between the enteral feeding intervals. Intolerance defined as gastric residual volume more than 250 ml with clinical symptoms or gastric residual volume more than 500 ml by itself. | — |
Secondary
| Measure | Time frame |
|---|---|
| Metoclopramide side effects. Timepoint: Daily. Method of measurement: Patients will be monitored regarding metoclopramide related adverse reactions including cardiovascular (blood pressure and cardiac rhythm), neurological (extrapyramidal signs and seizure) and gastrointestinal (diarrhea). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHossein Khalili
Tehran University of Medical Sciences
Outcome results
None listed